Acetylon Pharmaceuticals to Present Data Supporting ACY-1215 in Multiple Myeloma and Lymphoma at Upcoming Hematology Conferences

Published: Jun 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that it will present preclinical and clinical data for the Company’s lead candidate, ACY-1215, at upcoming international hematology conferences. ACY-1215 is a selective HDAC6 inhibitor currently being evaluated in a Phase 1b clinical trial in combination with the best-in-class drug Revlimid® (lenalidomide, Celgene) and a Phase 1/2 clinical trial in combination with the first-in-class drug Velcade® (bortezomib, Takeda Millennium), for the treatment of relapsed or refractory multiple myeloma. Acetylon is also investigating ACY-1215 for the treatment of lymphoma in preclinical studies.

Help employers find you! Check out all the jobs and post your resume.

Back to news